Ardelyx completes enrollment in constipation drug trial
Ardelyx Inc. (ARDX) completed enrollment in its Phase 3 ACCEL trial for IBSRELA (tenapanor) in treating chronic idiopathic constipation, ahead of schedule. Topline data is expected in the second half of 2027. IBSRELA is currently approved for irritable bowel syndrome with constipation in adults. The trial's primary endpoint is assessing the drug's durable efficacy in relieving constipation.
How this was made
The 30-second read
Why it matters
The accelerated enrollment reduces trial duration risk and may accelerate potential label expansion, supporting a higher valuation.
Market read
A material biotech milestone that could positively influence Ardelyx's stock and related sector sentiment.
What to watch
Regulatory timeline and potential competition from other constipation therapies could temper upside.
Background
Ardelyx's IBSRELA is already approved for IBS‑C; the ACCEL trial seeks an additional indication for chronic idiopathic constipation.
Ticker impact
Ardelyx announced it completed enrollment ahead of schedule for its Phase 3 ACCEL trial of IBSRELA in chronic idiopathic constipation.
likely upward pressure as market prices in the accelerated timeline and potential data readout in H2 2027.
Enrollment ahead of schedule signals strong trial execution and may reduce execution risk, which is valued by biotech investors.
Market effects
May lift sentiment for the constipation/IBS therapeutic niche and related biotech peers.
Limited to US biotech sector.
Minor, confined to specialty pharma investors.
Counterpoint
If the trial later fails to meet endpoints, the early enrollment news could be a false positive.
Key entities
- companyArdelyx Inc.
Biopharmaceutical company developing IBSRELA.
- personMichael Raab
President and CEO of Ardelyx.
